The short version of dual agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-20 and is reviewed periodically as new material appears.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Purity assay | 95 percent or greater by RP-HPLC | Typical research-grade specification |
| Storage temperature | 2 to 8 degrees Celsius | Formulated solution, do not freeze |
| Common analytical method | LC-MS with peptide mapping | Identity and impurity confirmation |
| Primary degradation routes | Deamidation, oxidation, aggregation | Tracked in stability programs |
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
== Background == During the early 19th century, a diverse group of Sotho-, Nguni- and Tswana-speaking tribes settled in the Caledon River region. The latter two, which formed the minority of the population, were gradually assimilated by the culturally dominant Sotho. King Moshoeshoe I united the various Sotho-speaking chieftainships into a single nation during a period of political turbulence known as Lifaqane. He transformed the denigratory exonym of Sotho into the name of the nascent Basuto nation. In 1833, missionaries from the Paris Evangelical Missionary Society began setting their outposts in Basuto lands following Moshoeshoe's invitation. They promoted a combination of Christianity, Western civilization, and commerce. They saw Basuto customs linked to obligatory labor and the dependence of the population on their chiefs as evil. They sought to undermine them by promoting private property, the commodization of production and closer economic ties with European settlers. In the 1820s, the Basuto faced cattle raids from the Koranna and first encountered horses and guns in a combat setting. They obtained horses and guns of their own, and began stockpiling gunpowder. By 1843, Moshoeshoe had accumulated more horses and guns than any other chieftain in South Africa, but the guns were outdated flintlocks, which had flooded the South African market after the introduction of percussion lock muskets.
restriction mapping The use of type II restriction endonucleases to cleave DNA molecules at specific restriction sites in order to produce characteristic patterns of fragments which can be resolved by size using gel electrophoresis. Digesting DNA molecules such as genomic DNA or plasmids with one or multiple restriction enzymes makes it possible to deduce from the sizes of the resulting fragments the order or arrangement of the restriction sites within the molecule and the distances between them, and thus to construct reliable maps with restriction sites effectively serving as genetic markers.
=== Sensors === Magnetohydrodynamic sensors are used for precise measurements of angular velocity in inertial navigation systems such as those used in aerospace engineering. Accuracy improves with sensor size. The sensor is capable of operating in harsh environments.
Russian media reported an attack by Ukrainian drones on the Afipsky oil refinery in Krasnodar Krai, as well as in oil depots in Tambov Oblast and Enem, Adygea. Authorities also claimed that drones were shot down over Bryansk, Rostov, Belgorod and Oryol Oblasts. One person was killed in a drone strike in Slavyansk-on-Kuban. Russia withdrew 80% of its soldiers from the Finnish border and redeployed them to Ukraine, according to an investigation by Finnish media. The Romanian government pledged to deliver a Patriot battery to Ukraine in exchange for a replacement unit from the US. John Kirby, National Security Council Coordinator for Strategic Communications, confirmed that the US government was to “reprioritise” all foreign exports of Patriot and NASAMS missiles in favour of Ukraine. Russia claimed that it used for the first time, a FAB-3000 modified with a guidance wing kit near Lyptsi, Kharkiv Oblast.
Sources: en.wikipedia.org
=== Promotion, awards and corporate citizenship === In September 2015, Roadie announced a partnership with Atlanta-based musician Ludacris, to promote the app. Following the devastation caused by flooding in Baton Rouge in 2016, Roadie offered free pickup and delivery for all deliveries traveling to and from the Baton Rouge area. In December 2020, Walmart named Roadie its top delivery partner for "Highest Driver Customer Satisfaction" and "Highest Net Promoter Score", after expanding into general merchandise deliveries as well as grocery that same year.
For the next three years, DiCaprio narrated documentaries and served as a producer for films. In 2016, he was an executive producer for The Ivory Game and Catching the Sun; he also produced, hosted and narrated the documentary Before the Flood about climate change. He produced the crime drama Live by Night (2016), which received unenthusiastic reviews and failed to recoup its $65 million production budget. His next production ventures were in 2018—the psychological horror Delirium and the commercially failed action–adventure Robin Hood. After producing and narrating the 2019 global warming documentary Ice on Fire, DiCaprio returned to acting following a four-year break in Quentin Tarantino's comedy-drama Once Upon a Time in Hollywood, which traces the relationship between Rick Dalton (DiCaprio), an aging television actor and his stuntman, Cliff Booth (Brad Pitt). To help the film's financing, DiCaprio and Pitt agreed to take a pay cut, and they each received $10 million. DiCaprio liked working with Pitt, and Tarantino described the pair as the most exciting since Robert Redford and Paul Newman. DiCaprio was fascinated with the film's homage to Hollywood and focus on the friendship between his and Pitt's characters. He drew from real-life experience of witnessing the struggles and rejections of his actor friends in the industry. The film premiered at the 2019 Cannes Film Festival, where critics praised his and Pitt's performances.
== Habitat == It is found in the Himalayan region from Ladakh Kashmir to Sikkim at an elevation of 2700–4500 m and in Nepal, found abundantly between 3500 and 4800 m. It has been reported that Picrorhiza has been harvested to near extinction.
Sources: en.wikipedia.org
== Product pipeline == Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes. The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes. In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin. In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market. In January 2023, a Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed, thus causing the share price to plunge. The company has mentioned that the pill worked for a subset of the population and will pursue a Phase 3 trial for that subset. In May 2023, Ben Shapiro invested $4.7 million and was named to the board of directors. On May 15, 2023, it was reported that Oramed's insulin pill was approved in China and will work with a Chinese firm to apply for marketing authorizations.
252.01 Hyperparathyroidism, primary 252.1 Hypoparathyroidism 253 Disorders of the pituitary gland and its hypothalamic control 253.3 Growth hormone deficiency 253.6 SIADH 254 Diseases of thymus gland 255 Disorders of adrenal glands 255.0 Cushing's syndrome 256 Ovarian dysfunction 256.2 Ovarian failure, postablative 256.39 Ovarian failure, other 256.4 Ovaries, polycystic 257 Testicular dysfunction 257.2 Testicular hypofunction 258 Polyglandular dysfunction and related disorders 259 Other endocrine disorders 259.0 Puberty, delayed 259.1 Sexual precocity
=== Portal hypertension === The portal vein also known as the hepatic portal vein carries blood drained from most of the gastrointestinal tract to the liver. Portal hypertension is mainly caused by cirrhosis of the liver. Other causes can include an obstructing clot in a hepatic vein (Budd Chiari syndrome) or compression from tumors or tuberculosis lesions. When the pressure increases in the portal vein, a collateral circulation develops, causing visible veins such as esophageal varices.
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.
Cycling between frozen and liquid states concentrates the peptide at ice interfaces, which favors non-covalent association. The resulting aggregates may be invisible to simple assays yet alter recovery and apparent potency. Limiting the number of cycles and aliquoting before storage are common mitigations.
Tryptophan and methionine side chains can undergo photo-induced oxidation, so amber glass or opaque packaging is typical. The effect is gradual and depends on wavelength and exposure time. Light protection is usually specified for both solid and solution forms.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.